Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

X
Trial Profile

A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATI-2173 (Primary) ; Imdusiran (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B; Hepatitis D
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Acronyms SAVE 1
  • Sponsors Antios Therapeutics
  • Most Recent Events

    • 15 Nov 2022 Status changed from active, no longer recruiting to discontinued.
    • 26 Jun 2022 Results assessing antiviral efficacy of ATI-2173 combined with tenofovir disoproxil fumarate in chronic hepatitis B patients, presented at The International Liver Congress 2022.
    • 25 Jun 2022 According to an Antios Therapeutics media release, data from this study were presented at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top